QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostic technologies, has announced the expansion of its QUICKVUE portfolio with the launch of the QUICKVUE™ Influenza + SARS Test. This new CLIA-waived, 510(k)-cleared rapid immunoassay is designed for professional use in settings such as physician office laboratories, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs.
The QUICKVUE Influenza + SARS Test offers healthcare providers a fast and efficient solution for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample. With results available in as little as 10 minutes, the test enables clinicians to quickly distinguish between COVID-19 and seasonal flu infections, which often present with similar symptoms. This rapid diagnostic capability supports timely treatment decisions and improved patient outcomes.
Key Features and Benefits
- Triple Detection Capability: Differentiates between influenza A, influenza B, and COVID-19 in one test.
- Fast Results: Provides clear results in as fast as 10 minutes at the point of care.
- Professional Use: Designed for CLIA-waived and moderate/high-complexity laboratory environments.
- Efficient Workflow: Features an easy-to-collect nasal swab, streamlined processing, and a clear result window.
- Affordable Access: Offers a cost-effective visual combo test option.
“Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis,” said Tammi Ranalli, PhD, Senior Vice President of Molecular Diagnostics and Point of Care Business Units at QuidelOrtho. “With the QUICKVUE Influenza + SARS Test, we’re equipping healthcare providers with a reliable, affordable, and efficient tool to differentiate between COVID-19 and influenza in minutes. This innovation reflects QuidelOrtho’s commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections.”
The launch of the QUICKVUE Influenza + SARS Test further strengthens QuidelOrtho’s leadership in point-of-care respiratory testing. It complements the company’s existing SOFIA™ 2 Flu + SARS Antigen FIA by offering a visually read option alongside its instrumented version. The test is now available in the United States through QuidelOrtho’s established distribution channels and is intended exclusively for professional use, not for in-home testing.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of diagnostic solutions with expertise in clinical chemistry, immunoassay, immunohematology, and molecular testing. The company is dedicated to delivering fast, accurate, and reliable results that improve patient outcomes across various healthcare settings, from point-of-care facilities to hospitals and clinics. With a legacy of innovation, QuidelOrtho collaborates with healthcare providers to advance diagnostics, connecting insights with solutions to enable informed decisions and better care.
To find out more please visit www.quidelortho.com
The post QuidelOrtho Unveils QUICKVUE™ Influenza + SARS Test for Professional Use appeared first on PRISM MarketView.
